Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

[1]  A. Shenker,et al.  Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects , 2018, Clinical pharmacology : advances and applications.

[2]  K. Kowalski,et al.  Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation , 2018, CPT: pharmacometrics & systems pharmacology.

[3]  A. Shenker,et al.  Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects , 2018, Journal of clinical pharmacology.

[4]  M. Horie,et al.  Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation , 2018, British journal of clinical pharmacology.

[5]  R. Kim,et al.  Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease , 2018, Drug Metabolism and Disposition.

[6]  Z. Wang,et al.  Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study , 2017, Journal of thrombosis and haemostasis : JTH.

[7]  M. Horie,et al.  Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation , 2017, Pharmacogenetics and genomics.

[8]  D. Lizotte,et al.  Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. , 2017, The Canadian journal of cardiology.

[9]  C. Frost,et al.  Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma , 2017, Thrombosis and Haemostasis.

[10]  C. Frost,et al.  Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism , 2017, CPT: pharmacometrics & systems pharmacology.

[11]  C. Frost,et al.  The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects , 2017, Clinical pharmacology : advances and applications.

[12]  P. Janský,et al.  The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. , 2016, European heart journal.

[13]  S. Connolly,et al.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.

[14]  C. Frost,et al.  Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. , 2016, Clinical therapeutics.

[15]  A. Shenker,et al.  Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban , 2016, Journal of clinical pharmacology.

[16]  C. Frost,et al.  Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis , 2016, Journal of clinical pharmacology.

[17]  A. Shenker,et al.  Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa , 2016, American Journal of Cardiovascular Drugs.

[18]  S. Connolly,et al.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.

[19]  S. Badawy,et al.  Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. , 2015, Clinical therapeutics.

[20]  A. Shenker,et al.  Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. , 2015, British journal of clinical pharmacology.

[21]  C. Frost,et al.  Randomized, blinded, placebo‐ and positive‐controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval , 2015, Journal of clinical pharmacology.

[22]  A. Shenker,et al.  Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban , 2015, Clinical Pharmacokinetics.

[23]  C. Frost,et al.  Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects , 2014 .

[24]  Jim X. Shen,et al.  LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. , 2014, Bioanalysis.

[25]  A. Shenker,et al.  Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. , 2014, British journal of clinical pharmacology.

[26]  Jun Zhu,et al.  Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. , 2014, American heart journal.

[27]  C. Frost,et al.  Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery , 2014, CPT: pharmacometrics & systems pharmacology.

[28]  C. Frost,et al.  tolerability, Pharmacokinetics and Pharmacodynamics of Apixaban, Aspirin and Clopidogrel Following Coadministration in Healthy Subjects : 2-54-2000057 , 2014 .

[29]  C. Frost,et al.  lack of Pharmacokinetic Interaction Between Apixaban and Prasugrel in Healthy Subjects : 2-55-2000112 , 2014 .

[30]  C. Frost,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. , 2014, International journal of clinical pharmacology and therapeutics.

[31]  D. Atar,et al.  Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial , 2014, European heart journal.

[32]  C. Frost,et al.  Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects , 2013, Clinical pharmacology : advances and applications.

[33]  C. Frost,et al.  Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. , 2013, British journal of clinical pharmacology.

[34]  Giridhar Tirucherai,et al.  Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects , 2013, American Journal of Cardiovascular Drugs.

[35]  A. Shenker,et al.  Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. , 2013, British journal of clinical pharmacology.

[36]  R. Knabb,et al.  A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[37]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[38]  C. Frost,et al.  Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor , 2013, Clinical pharmacology : advances and applications.

[39]  W. Humphreys,et al.  Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban , 2013, Drug Metabolism and Disposition.

[40]  G. Raskob,et al.  Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups , 2013, Journal of Thrombosis and Haemostasis.

[41]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[42]  C. Frost,et al.  Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects , 2012, British journal of clinical pharmacology.

[43]  C. Frost,et al.  A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects , 2012, Thrombosis and Haemostasis.

[44]  G. Lip,et al.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.

[45]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[46]  K. He,et al.  Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma , 2011, Journal of enzyme inhibition and medicinal chemistry.

[47]  P. Lam,et al.  Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor , 2011, European Journal of Drug Metabolism and Pharmacokinetics.

[48]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[49]  D. Pinto,et al.  Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor , 2011, Journal of Thrombosis and Thrombolysis.

[50]  W. Humphreys,et al.  Tissue Distribution and Elimination of [14C]Apixaban in Rats , 2011, Drug Metabolism and Disposition.

[51]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[52]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. , 2010, The New England journal of medicine.

[53]  A. Shenker,et al.  Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay , 2010, Thrombosis and Haemostasis.

[54]  T. Leil,et al.  Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose , 2010, Clinical pharmacology and therapeutics.

[55]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial , 2010, The Lancet.

[56]  W. Humphreys,et al.  In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies , 2010, Drug Metabolism and Disposition.

[57]  G. Raskob,et al.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement. , 2009, The New England journal of medicine.

[58]  W. Humphreys,et al.  Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans , 2009, Drug Metabolism and Disposition.

[59]  P. Wong,et al.  Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro , 2009, Thrombosis and Haemostasis.

[60]  W. Humphreys,et al.  Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.

[61]  Angela Smallwood,et al.  Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2007, Journal of medicinal chemistry.

[62]  J. Ansell.  Factor Xa or thrombin: is factor Xa a better target? , 2007, Journal of thrombosis and haemostasis : JTH.

[63]  S. Yusuf,et al.  Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. , 2016, Age and ageing.

[64]  J. Unadkat,et al.  Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update , 2014, The AAPS Journal.